Product Description
Mechanisms of Action: MAO-b Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Healthy Volunteers|Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
3 Armed RCT | N/A |
Not yet recruiting |
Obesity |
2023-09-30 |
|
MAyflOwer RoAD | P2 |
Completed |
Alzheimer Disease |
2015-06-12 |
|
2012-000943-29 | P2 |
Completed |
Alzheimer Disease |
2015-06-03 |
|
JapicCTI-142605 | P1 |
Completed |
Alzheimer Disease |
2015-05-01 |